NCT03114319: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Sponsor: Novartis Pharmaceuticals. Phase: PHASE1. Conditions: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma